Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways

Oncotarget

Volumn 5, Issue 20, 2014, Pages 9939-9951

  Chéry, Lisly ^a   Lam, Hung Ming ^a   Coleman, Ilsa ^b   Lakely, Bryce ^a   Coleman, Roger ^b   Larson, Sandy ^a   Aguirre Ghiso, Julio A ^c   Xia, Jing ^b   Gulati, Roman ^b   Nelson, Peter S ^b,d   Montgomery, Bruce ^d   Lange, Paul ^a,e   Snyder, Linda A ^f   Vessella, Robert L ^a,e   Morrissey, Colm ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Dormancy; Gene expression; Metastasis; p38; Prostate cancer

Indexed keywords

CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER DORMANCY; CANCER PATIENT; CANCER RECURRENCE; CELL HETEROGENEITY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE MARKER; ERYTHROID CELL; FIELD STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MALE; METASTASIS; PROSTATE CANCER; PROSTATE EPITHELIUM; SINGLE CELL ANALYSIS; TRANSCRIPTOMICS; CANCER STEM CELL; DISEASE FREE SURVIVAL; DOWN REGULATION; ERYTHROID PRECURSOR CELL; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR EMBOLISM; TUMOR RECURRENCE;

DISEASE-FREE SURVIVAL; DOWN-REGULATION; ERYTHROID PRECURSOR CELLS; GENE EXPRESSION; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; SINGLE-CELL ANALYSIS;

EID: 84925626474     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2480     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
2. Cooperberg MR, Broering JM and Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28(7):1117-23.
3. Morton RA, Steiner MS and Walsh PC. Cancer control following anatomical radical prostatectomy: an interim report. J Urol. 1991; 145(6):1197-200.
4. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B and Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001; 91(1):66-73.
5. Weiss L. Random and nonrandom processes in metastasis, and metastatic inefficiency. Invasion Metastasis. 1983; 3(4):193-207.
6. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'- deoxyuridine. J Natl Cancer Inst. 1970; 45(4):773-82.
7. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975; 35(3):512-6.
8. Chambers AF, Groom AC and MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-72.
9. Hadfield G. Dormancy in Cancer. Br Med J. 1954; 2(4888):635.
10. Aguirre-Ghiso JA, Estrada Y, Liu D and Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 2003; 63(7):1684-95.
11. Ruppender NS, Morrissey C, Lange PH and Vessella RL. Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 2013; 32(3-4):501-9.
12. Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D'Amico AV and Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology. 2010; 76(5):1201-5.
13. Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL and Morrissey C. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol. 2013; 146.
14. Lammers R, Giesert C, Grunebach F, Marxer A, Vogel W and Buhring HJ. Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol. 2002; 30(6):537-45.
15. Eisenwort G, Jurkin J, Yasmin N, Bauer T, Gesslbauer B and Strobl H. Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-beta1-dependent human epidermal Langerhans cells. J Invest Dermatol. 2011; 131(10):2049-57.
16. Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, Schewe DM and Aguirre-Ghiso JA. TGFbeta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 2013; 15(11):1351-61.
17. Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, Albaugh M, Vidal-Vanaclocha F, Palmieri D, Barbier M, Murone M and Steeg PS. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst. 2012; 104(17):1306-19.
18. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, Pai SK, Liu W, Fukuda K, Chambers C, Wilber A and Watabe K. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55.
19. Abi Saab WF, Brown MS and Chadee DN. MLK4beta functions as a negative regulator of MAPK signaling and cell invasion. Oncogenesis. 2012; 1e6.
20. Ratkaj I, Bujak M, Jurisic D, Baus LM, Bendelja K, Pavelic K and Kraljevic PS. Microarray analysis of Dupuytren's disease cells: the profibrogenic role of the TGF-beta inducible p38 MAPK pathway. Cell Physiol Biochem. 2012; 30(4):927-42.
21. Richard E, Desviat LR, Ugarte M and Perez B. Oxidative stress and apoptosis in homocystinuria patients with genetic remethylation defects. J Cell Biochem. 2013; 114(1):183-91.
22. Mueller JW, Bayer P. Small family with key contacts: par14 and par17 parvulin proteins, relatives of pin1, now emerge in biomedical research. Perspect Medicin Chem. 2008; 211-20.
23. Ruland J, Duncan GS, Wakeham A and Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity. 2003; 19(5):749-58.
24. Cha H, Wang X, Li H and Fornace AJ, Jr. A functional role for p38 MAPK in modulating mitotic transit in the absence of stress. J Biol Chem. 2007; 282(31):22984-92.
25. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS and Aguirre- Ghiso JA. Computational identification of a p38SAPKregulated transcription factor network required for tumor cell quiescence. Cancer Res. 2009; 69(14):5664-72.
26. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K and Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001; 12(4):863-79.
27. Sjogren U. Different composition of the erythropoietic tissue in bone marrow, spleen and liver in myelofibrosis. Acta Haematol. 1978; 59(4):231-6.
28. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS and Vessella RL. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res. 2013; 28(2):333-40.
29. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL and Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008; 180(3):1154-60.
30. Uchida T, Takamiya M, Takahashi M, Miyashita H, Ikeda H, Terada T, Matsuo Y, Shirouzu M, Yokoyama S, Fujimori F and Hunter T. Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation. Chem Biol. 2003; 10(1):15-24.
31. Ranganathan AC, Zhang L, Adam AP and Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006; 66(3):1702-11.
32. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D and Bissell MJ. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013; 15(7):807-17.
33. Hanzelmann S, Castelo R and Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 147.